PALO ALTO, Calif.--(BUSINESS WIRE)--Carbylan BioSurgery, Inc., a biotechnology company focused on the development and commercialization of advanced biomaterial-based joint therapies to treat pain associated with osteoarthritis, announced that it has appointed David M. Renzi as president, chief executive officer and member of the board of directors. The appointment of Mr. Renzi, a proven operational executive, signals a renewed focus on the Company’s long-term growth strategy and a dedication to product development and commercialization. The Company also announced that Samuel Lynch, D.M.D., D.M.Sc. has been appointed chairman of Carbylan’s board of directors.
Commenting on Mr. Renzi’s appointment, Dr. Lynch stated, “Given David’s extensive experience in both public and private medical device companies, the board of directors is delighted that he has joined Carbylan as we continue the development process of the Company’s next generation injectable technology for the treatment of joint pain.” Mr. Renzi will lead Carbylan as it enters its pivotal clinical trial utilizing the Company’s proprietary hyaluronan-based hydrogel which is combined with a low dose corticosteroid. This unique technology is designed to provide rapid and long-lasting relief of the pain associated with osteoarthritis using a single intra-articular injection.
Mr. Renzi has over 30 years of successful healthcare experience and spent the majority of this time with Ethicon and Ethicon Endosurgery, divisions of Johnson & Johnson. There he was given responsibility for numerous business disciplines including sales, sales management, marketing management and new procedure development. Most recently, Mr. Renzi was president and chief executive officer of Neomend, Inc., a company developing and commercializing hydrogels and surgical sealants for treating lung air leaks after surgical resection. Neomend was purchased by C.R. Bard in October 2012. Prior to Neomend, Mr. Renzi was executive vice president and chief commercial officer of Novacept, Inc. and SurgRx, Inc., both privately held venture-backed companies with successful exits in 2004 and 2008, respectively.
“I am extremely excited to join the Carbylan team as we continue our development of a next generation injectable aimed at capturing significant share in the $2.5 billion viscosupplementation market. This market is growing by over 11 percent per year and there are nearly 27 million people in the United States alone who suffer from osteoarthritis. I am confident our technology will continue to produce meaningful clinical data as we advance our pivotal trial later this year. This clinically relevant pivotal trial data, coupled with results from our successful recent phase IIb study, I believe will allow us to gain regulatory approval and ultimately provide this unique therapy to the many patients still suffering from the pain of osteoarthritis,” said Mr. Renzi. “There are many exciting and promising opportunities before us, and I am very pleased to be involved with Carbylan at this important phase in the Company’s development cycle.”
“David's significant expertise in growing biotechnology companies into industry leaders will be critical as we work to move Carbylan’s products through clinical trials, regulatory approval and ultimately commercialization," continued Dr. Lynch. "The Company’s platform technology provides an innovative, proprietary means of addressing a substantial unmet medical need. David will help us realize our vision for the organization and future growth plans for our technology."
Dr. Lynch founded BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of products to promote the healing of musculoskeletal injuries and diseases in orthopedic and sports medicine applications, and served as president, chief executive officer and a director for more than 10 years. He also served as chairman of the board of directors until the company’s initial public offering (IPO). At BioMimetic, Dr. Lynch oversaw the company’s financings, including an IPO and follow-on financings as well as its recent merger with Wright Medical Group, Inc. He also brings additional expertise in product development and regulatory affairs to the Carbylan board.
About Carbylan BioSurgery, Inc.
Carbylan (www.carbylan.com) was founded in 2005 to develop and market medical devices and device/drug combination products based on novel chemically engineered polymer systems incorporating hyaluronic acid, a well-known polysaccharide widely present in the human body. Its initial market focus is therapeutic medical devices and combination products to treat the pain associated with osteoarthritis. Carbylan biopolymers are novel biomaterials which when combined with pharmaceutical agents enable the development of unique medical products.